Glyceryl Dibehenate – A matrix-forming excipient for controlled release

1. Lipid Matrices & The Rise of Glyceryl Dibehenate

Lipid matrix frames used for sustained-release tablets are an increasingly popular trend in the pharmaceutical manufacturing industry, offering advantages in controllability, stability, and flexibility with various formulation processes.

Many lipid excipients have been used to create matrices controlling the release rate of active ingredients, such as: glyceryl dibehenate, hydrogenated castor oil, cetyl alcohol, stearyl alcohol, ceto stearyl alcohol, stearic acid, glyceryl monostearate, etc. Among them, glyceryl dibehenate is a common excipient for sustained-release tablets, providing excellent control over the active ingredient's release rate.

Glyceryl dibehenate is a mixture of mono-, di-, and triglyceride esters of behenic acid (docosanoic acid). This excipient is commonly used in pharmaceuticals with the following applications:

• Lipid matrix-forming agent to control the active ingredient release rate for sustained-release tablets.
• Non-incompatible lubricant excipient that provides an aesthetically pleasing appearance for tablets.

2. Optimizing Sustained-Release Tablets: Superior Control & Eliminating Dose Dumping

Glyceryl dibehenate creates a lipophilic matrix frame, with a usage rate of 15 – 50% in the tablet depending on the formulation and the hydrophilicity of the active ingredient. Advantages of Glyceryl dibehenate for sustained-release tablets:

• The lipid matrix is non-swelling and non-eroding, thus maintaining the active ingredient's diffusion mechanism -> avoids dose dumping (rapid burst release) in the first 60 minutes or when the tablet breaks.
• Applicable to various formulation processes: direct compression, wet granulation, hot melt extrusion, solid dispersion systems, etc.
• No organic solvents required -> avoids explosion risks, avoids the effect of alcohol on the active ingredient release.
• Stable under physiological conditions: digestive enzymes, pH -> limits the variation in active ingredient release among different patients.
• Chemically inert, compatible with active ingredients and excipients.
• The release of the active ingredient is minimally affected during scale-up.

Reference formulation for Sodium diclofenac 75 mg sustained-release tablets:

3. The Multi-Functional Lubricant: Completely Overcoming Magnesium Stearate Incompatibilities

• Lipophilic lubricant excipient, providing a glossy tablet surface, reducing the ejection force from the die -> extends the lifespan of punches and dies.
• Usage rate of 1 – 3% in the tablet, extra-granular mixing.
• Non-incompatible lubricant excipient, suitable for active ingredients that are incompatible with Magnesium stearate.
• Does not cause a metallic taste.
• Stable lubricant excipient, minimally affected by varying mixing conditions on tablet properties: amount of excipient used, mixing time.
• Has good binding properties, supporting tablet cohesion, helping the tablet overcome hardness limitations when using lubricant excipients.
• Favorable during scale-up.